• citations in SCIndeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:3
  • full-text downloads in 30 days:0


article: 10 from 17  
Back back to result list
2008, vol. 30, iss. 3-4, pp. 53-59
Biology of anxiety and implications for new psychopharmacological treatment of anxiety disorders
Clinical Center Kragujevac, Clinic of Psychiatry

Keywords: anxiety; neurobiological basis of anxiety; psychopharmacs; neurotransmitters; neuropeptides
Anxiety disorders are among the most prevalent mental disorders in the general population. Nearly 30 million persons are affected in the United States, with women affected nearly twice as frequently as men. Anxiety disorders are associated with significant morbidity and often are chronic and resistant to treatment. Fear was described to be the most common experiential phenomenon produced by direct electrical brain stimulation in temporal lobe epilepsy, localized to the anteromedial temporal region including the amygdala. The areas of the brain responsible for the acquisition and expression of fear conditioning are only medium for wide interaction of neurotransmitters and neuropeptides on their receptors different by structure and its distribution and this is the main topic of this review. The Committee of the DSM-V Prelude Project, is considering re-classifying the anxiety disorders by several hypothetical approaches, including by etiology (vulnerability genes and gene/environment interactions) or by pathophysiology (neural pathways that give rise to certain symptoms). Discrepancy between slowdown in production of new drugs and many clinical studies in this area show us that it is necessary to develop new selective and more sufficiant drugs. When complex neurochemistry of the brain structures become more clear it would point us on clinically useful conclusions and long expected anxioselective agent.


article language: Serbian
document type: Review Paper
published in SCIndeks: 30/06/2009

Related records

No related records